Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: A United Kingdom Haemophilia Centre Doctors’ Organisation guideline
- 17 December 2019
- journal article
- review article
- Published by Wiley in Haemophilia
- Vol. 26 (1), 6-16
- https://doi.org/10.1111/hae.13907
Abstract
Assay discrepancies can occur with laboratory monitoring of FVIII and FIX replacement therapy, particularly for the extended half‐life products. This guideline collates current published data and provides advice on appropriate choice of assays for laboratory measurement of replacement therapy for patients with Haemophilia A and B without inhibitors. It is recommended that each haemophilia centre should ensure that appropriate laboratory assays are available for FVIII and FIX products in local clinical use. Patient samples should be assayed against calibrators traceable to WHO Plasma International Standards. Assay discrepancies are common especially for the extended half‐life FVIII and FIX products, and assays of these products may need to be verified with the specific CFC being used.Keywords
This publication has 40 references indexed in Scilit:
- Guidelines on the laboratory aspects of assays used in haemostasis and thrombosisInternational Journal of Laboratory Hematology, 2012
- Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patientsBlood, 2012
- The use of the new ReFacto AF Laboratory Standard allows reliable measurement of FVIII:C levels in ReFacto AF mock plasma samples by a one‐stage clotting assayHaemophilia, 2011
- International comparative field study of N8 evaluating factor VIII assay performanceHaemophilia, 2011
- Influence of source of phospholipids for APTT‐based factor IX assays and potential consequences for the diagnosis of mild haemophilia BHaemophilia, 2009
- Emerging Technologies and Quality Assurance: The United Kingdom National External Quality Assessment Scheme PerspectiveSeminars in Thrombosis and Hemostasis, 2007
- Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assaysJournal of Thrombosis and Haemostasis, 2004
- A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standardsJournal of Thrombosis and Haemostasis, 2003
- In vivo recovery with products of very high purity — assay discrepanciesHaemophilia, 1998
- Familial discrepancy between the one‐stage and two‐stage factor VIII methods in a subgroup of patients with haemophilia ABritish Journal of Haematology, 1994